Tomas Kiselak
CIK 1830177 · last filed 2026-07-20
Tomas Kiselak is a corporate insider who has filed 20 SEC Form 4 insider transactions across 9 companies since 2020. The most recent filing shows the insider bought $49.5M of GLYC on Jul 20, 2026. Across all open-market trades the lifetime net is −$463.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $312.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$312.62M
9
20
-$463.38M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 3,601,316 | $15.70 | $56.54M | $49.50M | 1 | 2026-07-20 |
| VRDN | Director | — | $19.51 | — | $0 | 7 | 2026-07-02 |
| APGE | Director | 51,166 | $134.17 | $6.86M | -$534.10M | 3 | 2026-06-11 |
| SYRE | Director | 406,038 | $99.96 | $40.59M | $0 | 2 | 2026-05-29 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 2,904,000 | $28.69 | $83.32M | $0 | 1 | 2026-02-12 |
| ORKA | Director | 2,573,308 | $90.45 | $232.76M | $0 | 1 | 2025-09-19 |
| DNTH | Director | 0 | $101.61 | $0 | $815.0K | 3 | 2024-10-01 |
| ZBIO | Director | 1,003,814 | $32.29 | $32.41M | $20.40M | 1 | 2024-09-16 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | Director | — | — | — | $0 | 1 | 2020-10-29 |
Recent Filings
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-20 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +3,413,800 | $49.50M | EDGAR |
| 2026-07-02 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | APGE | Grant (A) | — | $0 | EDGAR |
| 2026-05-29 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2026-02-12 | Damora Therapeutics, Inc. (GLTO) Delisted | Exer (M) | +43,565,000 | $0 | EDGAR |
| 2026-01-22 | APGE | Sell (S) | −7,000,000 | -$534.10M | EDGAR |
| 2025-09-19 | ORKA | Grant (A) | +1,666,700 | $25.00M | EDGAR |
| 2025-07-02 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2024-10-01 | DNTH | Other (J) | −124,292 | $0 | EDGAR |
| 2024-09-16 | ZBIO | Mixed | +6,419,564 | $20.40M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.